Rebastinib

DB13005InvestigationalSmall molecule

Rebastinib has been used in trials studying the treatment of Chronic Myeloid Leukemia. It is an inhibitor of Tie2 tyrosine kinase receptor and an antineoplastic agent.

Mechanism: Pharmacologically active on Tyrosine-protein kinase ABL1
Curator reviewed
Formula / weight: C₃₀H₂₈FN₇O₃ · 553.5868 g/mol (avg)
Code names: DCC-2036 FREE BASE · DP-1919

Resolves to

Compound

UNII75017Q6I97CAS1020172-07-9ChEMBLCHEMBL1738757ChEBI62166PubChem25066467

Structure

InChIKeyWVXNSAVVKYZVOE-UHFFFAOYSA-NSMILESCNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC(=NN3C3=CC4=CC=CN=C4C=C3)C(C)(C)C)C(F)=C2)=CC=N1

Targets

P00519ABL1Q02763TEK

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rebastinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account